TEVA logo

TEVA
Teva- Pharmaceutical Industries Ltd. - ADR

26,920
Mkt Cap
$78.36B
Volume
0.00
52W High
$22.80
52W Low
$12.47
PE Ratio
-131.05
TEVA Fundamentals
Price
$19.04
Prev Close
$19.02
Open
$19.07
50D MA
$19.07
Beta
0.79
Avg. Volume
10.79M
EPS (Annual)
-$1.45
P/B
3.18
Rev/Employee
$456,493.49
Loading...
Loading...
News
all
press releases
All You Need to Know About Teva Pharmaceutical Industries (TEVA) Rating Upgrade to Buy
Teva Pharmaceutical Industries (TEVA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks·4d ago
News Placeholder
More News
News Placeholder
Does Teva Pharmaceutical Industries (TEVA) Have the Potential to Rally 28.12% as Wall Street Analysts Expect?
The consensus price target hints at a 28.1% upside potential for Teva Pharmaceutical Industries (TEVA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·4d ago
News Placeholder
Should Value Investors Buy Teva Pharmaceutical Industries (TEVA) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks·4d ago
News Placeholder
Johnson & Johnson Targets Accelerated Growth Across Segments in 2026
J&J projects faster 2026 growth in Innovative Medicine and MedTech, topping consensus estimates on both revenues and EPS.
Zacks·4d ago
News Placeholder
Here's Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks·9d ago
News Placeholder
JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit
J&J tops Q3 forecasts, lifts 2025 sales outlook and plans to spin off its struggling Orthopaedics business.
Zacks·11d ago
News Placeholder
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
Zacks·12d ago
News Placeholder
Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know
J&J gears up for Q3 results with solid gains from Darzalex, Tremfya and MedTech, even as Stelara faces fierce biosimilar pressure.
Zacks·15d ago
News Placeholder
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
Zacks·23d ago
News Placeholder
Why Teva Pharmaceutical Industries Ltd. (TEVA) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks·25d ago

Latest TEVA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.